BROMODOMAIN INHIBITOR JQ1 IN COMBINATION WITH DNA METHYLATION INHIBITOR DAC FOR USE IN CANCER TREATMENT

Result code in IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F20%3A73605877" target="_blank" >RIV/61989592:15110/20:73605877 - isvavai.cz</a>
Result on the web
<a href="https://worldwide.espacenet.com/publicationDetails/originalDocument?FT=D&date=20200610&DB=&locale=en_EP&CC=EP&NR=3042650B1&KC=B1&ND=4" target="_blank" >https://worldwide.espacenet.com/publicationDetails/originalDocument?FT=D&date=20200610&DB=&locale=en_EP&CC=EP&NR=3042650B1&KC=B1&ND=4</a>
DOI - Digital Object Identifier
—

Result language
angličtina
Original language name
BROMODOMAIN INHIBITOR JQ1 IN COMBINATION WITH DNA METHYLATION INHIBITOR DAC FOR USE IN CANCER TREATMENT
Original language description
The invention is directed to a bromodomain inhibitor in combination with a DNA methylation inhibitor for use in treatment of cancers, in order to overcome resistance towards DNA methylation inhibitors. Resistance to chemotherapeutic treatment is one of the major impediments forefending the successsful cancer therapy (Gottesman M.M. et al., Nature Reviews Cancer 2002; 2, 48-58). Although the research has unraveled the main molecular signatures of resistance to chemotherapy, including intracellular inactivation of the drug (Garattini S. et al., European Journal of Cancer 2007; 43, 271-82), defects in DNA mismatch repair (Fink D. et al., Clinical Cancer Research 1998; 4, 1-6)...
Czech name
—
Czech description
—

Project
<a href="/en/project/TN01000013" target="_blank" >TN01000013: Personalized Medicine – Diagnostics and Therapy</a><br>
Continuities
P - Projekt vyzkumu a vyvoje financovany z verejnych zdroju (s odkazem do CEP)

Publication year
2020
Confidentiality
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Similar results(10)